WO2013153451A3 - Controlled release formulations of opioids - Google Patents

Controlled release formulations of opioids Download PDF

Info

Publication number
WO2013153451A3
WO2013153451A3 PCT/IB2013/001050 IB2013001050W WO2013153451A3 WO 2013153451 A3 WO2013153451 A3 WO 2013153451A3 IB 2013001050 W IB2013001050 W IB 2013001050W WO 2013153451 A3 WO2013153451 A3 WO 2013153451A3
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
opioids
release formulations
opioid
methods
Prior art date
Application number
PCT/IB2013/001050
Other languages
French (fr)
Other versions
WO2013153451A2 (en
Inventor
Edward M. Rudnic
Michael Vachon
Gary W. Pace
Original Assignee
QRxPharma Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/442,849 external-priority patent/US20130022646A1/en
Application filed by QRxPharma Ltd. filed Critical QRxPharma Ltd.
Priority to AU2013204592A priority Critical patent/AU2013204592A1/en
Publication of WO2013153451A2 publication Critical patent/WO2013153451A2/en
Publication of WO2013153451A3 publication Critical patent/WO2013153451A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.
PCT/IB2013/001050 2012-04-09 2013-04-09 Controlled release formulations of opioids WO2013153451A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204592A AU2013204592A1 (en) 2012-04-09 2013-04-09 Controlled release formulations of opioids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/442,849 2012-04-09
US13/442,849 US20130022646A1 (en) 2010-02-09 2012-04-09 Controlled Release Formulations of Opioids

Publications (2)

Publication Number Publication Date
WO2013153451A2 WO2013153451A2 (en) 2013-10-17
WO2013153451A3 true WO2013153451A3 (en) 2014-01-23

Family

ID=49328252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/001050 WO2013153451A2 (en) 2012-04-09 2013-04-09 Controlled release formulations of opioids

Country Status (2)

Country Link
AU (1) AU2013204592A1 (en)
WO (1) WO2013153451A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010765A1 (en) * 1991-11-27 1993-06-10 Euroceltique S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
AU4449399A (en) * 1993-10-07 1999-10-14 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
WO2012040651A2 (en) * 2010-09-24 2012-03-29 QRxPharma Ltd. Controlled release formulations of opioids
WO2012112952A1 (en) * 2011-02-17 2012-08-23 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010765A1 (en) * 1991-11-27 1993-06-10 Euroceltique S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
AU4449399A (en) * 1993-10-07 1999-10-14 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
WO2012040651A2 (en) * 2010-09-24 2012-03-29 QRxPharma Ltd. Controlled release formulations of opioids
WO2012112952A1 (en) * 2011-02-17 2012-08-23 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DE LA IGLESIA, F. A. ET AL.: "Tolerability and Efficacy of Two Synergistic Ratios of Oral Morphine and Oxycodone Combinations Versus Morphine in Patients with Chronic Non-Cancer Pain", JOURNAL OF OPIOID MANAGEMENT, vol. 8, no. 2, March 2012 (2012-03-01), pages 89 - 98 *

Also Published As

Publication number Publication date
WO2013153451A2 (en) 2013-10-17
AU2013204592A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
HUS2200017I1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2012040651A3 (en) Controlled release formulations of opioids
HK1199814A1 (en) Inhibition of adaptor associated kinase for the treatment of pain
EP3541386A4 (en) Compositions and methods for the treatment of opioid overdose
EP3031826A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
HUE041553T2 (en) Methods and compositions for the treatment of monogenic diseases
WO2014130856A3 (en) Treatment of skeletal-related disorders
HK1220324A1 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP2968318A4 (en) Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases
PL3065732T3 (en) Compounds, compositions and uses thereof for the prevention and/or treatment of dyslipidemia
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
EP3068387A4 (en) Compounds and methods for the treatment of malaria
EP3206685A4 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
HRP20181761T1 (en) New alfentanil composition for the treatment of acute pain
AP2014007905A0 (en) Novel compounds for the treatment of dyslipidemia and related diseases
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
WO2013153451A3 (en) Controlled release formulations of opioids
EP3079657B8 (en) Preparation for prevention and/or treatment of peri-implantitis
EP3085369A4 (en) Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain
EP3344626A4 (en) Therapeutic compounds for pain and synthesis thereof
HK1212587A1 (en) Formulation for prevention or treatment of diabetes
GB201219696D0 (en) Agents for the prevention and/or treatment of central nervous system damamge
AU2012900286A0 (en) "Methods of treatment or prophylaxis"
HUP1300454A2 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2013204592

Country of ref document: AU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13/02/2015)

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13775786

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13775786

Country of ref document: EP

Kind code of ref document: A2